TKD comprised three components: the cancer cell‐penetrating peptide BR2, a nanobody binding to KRAS, and a lysosomal recognition and binding motif CTM.[11c] BR2 enabled the targeted recognition of tumor cells,[27] while CTM promoted the recognition, binding, and degradation of KRAS proteins by the lysosome.[28] The nanobody, with a significantly smaller molecular weight than conventional antibodies, enhanced tissue penetration and KRAS targeting. This evidence concerns the gene KRAS and neoplasm.